drugset / Trial / NCT04371926
Prophylactic Benefit of Hydroxychloroquine in COVID-19 Cases With Mild to Moderate Symptoms and in Healthcare Workers With High Exposure Risk
RandomizedParallel-groupSingle-blindPrevention
Summary
Few studies have reported the efficacy of HCQ in reducing the viral load and improving the severity of symptoms in hospitalized COVID-19 cases with serious respiratory infection. However, the prophylactic benefits of HCQ has not been clearly defined yet.
Timeline
- Start
- 2020-06
- Primary completion
- 2021-06
- Completion
- 2021-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Hydroxychloroquine | Small molecule | 200 mg | — |
| Comparator | Hydroxychloroquine | Small molecule | 400 mg | — |